Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US-11370774-B2 · Jun 28, 2022 · US
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US11708347B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11708347-B2 |
| Application number | US-202117168574-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 5, 2021 |
| Priority date | Apr 6, 2018 |
| Publication date | Jul 25, 2023 |
| Grant date | Jul 25, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating or a disease or condition characterized by aberrant complement system activity, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, catastrophic antiphospholipid syndrome, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), IgA nephropathy, age-related macular degeneration (AMD), erythematosus, warm autoimmune hemolytic anemia, and focal segmental glomerulosclerosis. 2. The method of claim 1 , wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, organ transplant rejection, myasthenia gravis, neuromyelitis optica, membranoproliferative glomerulonephritis, dense-deposit disease, cold agglutinin disease, and catastrophic antiphospholipid syndrome. 3. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The method of claim 2 , wherein the disease or condition characterized by aberrant complement system activity is selected from the group consisting of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, dense-deposit disease, and age-related macular degeneration (AMD). 7. The method of claim 3 , wherein the disease or condition characterized by aberrant complement system activity is paroxysmal nocturnal hemoglobinuria. 8. The method of claim 4 , wherein the disease or condition characterized by aberrant complement system activity is paroxysmal nocturnal hemoglobinuria. 9. The method of claim 5 , wherein the disease or condition characterized by aberrant complement system activity is paroxysmal nocturnal hemoglobinuria.
Assignees
Inventors
Classifications
- C07D239/70Primary
condensed with carbocyclic rings or ring systems · CPC title
- C07D401/10Primary
linked by a carbon chain containing aromatic rings · CPC title
Radicals substituted by oxygen atoms · CPC title
condensed with carbocyclic rings or ring systems · CPC title
Radicals substituted by oxygen atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11708347B2 cover?
- Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
- Who is the assignee on this patent?
- Biocryst Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D239/70. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).